This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by San Gabriel, P. Articles by Saiman, L. Search for Related Content PubMed PubMed Citation Articles by San Gabriel, P. Articles by Saiman, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 168-171, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.168-171.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis

Department of Pediatrics, Columbia University, New York, New York 10032

Received 29 January 2003/ Returned for modification 22 May 2003/ Accepted 22 September 2003

Stenotrophomonas maltophilia is a newly emerging pathogen being detected with increasing frequency in patients with cystic fibrosis (CF). The impact of this multidrug-resistant organism on lung function is uncertain. The optimal treatment for S. maltophilia in CF patients is unknown. We studied the in vitro activity of ten antimicrobial agents, and conducted synergy studies by using checkerboard dilutions of eight pairs of antimicrobial agents against strains isolated from 673 CF patients from 1996 to 2001. This represents approximately 7 to 23% of the CF patients in the United States who harbor S. maltophilia annually. Doxycycline was the most active agent and inhibited 80% of 673 initial patient isolates, while trimethoprim-sulfamethoxazole inhibited only 16%. High concentrations of colistin proved more active than high concentrations of tobramycin and gentamicin. Serial isolates (n = 151) from individual patients over time (median, 290 days) showed minimal changes in resistance. Synergistic or additive activity was demonstrated by trimethoprim-sulfamethoxazole paired with ticarcillin-clavulanate (65% of strains), ciprofloxacin paired with ticarcillin-clavulanate (64% of strains), ciprofloxacin paired with piperacillin-tazobactam (59% of strains), trimethoprim-sulfamethoxazole paired with piperacillin-tazobactam (55% of strains), and doxycycline paired with ticarcillin-clavulanate (49% of strains). In all, 522 (78%) isolates were multidrug resistant (i.e., resistant to all agents in two or more antimicrobial classes) but 473 (91%) of these were inhibited by at least one antimicrobial combination (median, four; range, one to eight). To determine appropriate treatment for patients with CF, it is important to monitor the prevalence, antimicrobial susceptibility, and clinical impact of S. maltophilia in this patient population.

This article has been cited by other articles:

• Falagas, M. E., Valkimadi, P.-E., Huang, Y.-T., Matthaiou, D. K., Hsueh, P.-R. (2008). Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 0: dkn301v1-6 [Abstract] [Full Text]  
• Zhou, J., Chen, Y., Tabibi, S., Alba, L., Garber, E., Saiman, L. (2007). Antimicrobial Susceptibility and Synergy Studies of Burkholderia cepacia Complex Isolated from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 51: 1085-1088 [Abstract] [Full Text]  
• Navarro-Martinez, M. D., Navarro-Peran, E., Cabezas-Herrera, J., Ruiz-Gomez, J., Garcia-Canovas, F., Rodriguez-Lopez, J. N. (2005). Antifolate Activity of Epigallocatechin Gallate against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 49: 2914-2920 [Abstract] [Full Text]